Report of Foreign Issuer (6-k)
January 13 2020 - 10:05AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
________________
FORM 6-K
________________
REPORT OF FOREIGN PRIVATE ISSUER
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
January 13, 2020
________________
NOVO NORDISK A/S
(Exact name
of Registrant as specified in its charter)
Novo Allé
DK- 2880, Bagsvaerd
Denmark
(Address of principal executive offices)
________________
Indicate by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F
Form 20-F [X]
|
Form 40-F [ ]
|
Indicate by check mark whether the registrant by furnishing the information contained
in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange
Act of 1934.
If “Yes” is marked, indicate below the file number assigned to the registrant
in connection with Rule 12g-32(b):82-________
Novo Nordisk A/S – Share repurchase programme
Bagsværd,
Denmark, 13 January 2020 – On 5 November 2019, Novo Nordisk initiated a share
repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European
Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation
(EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of
the overall share repurchase programme of up to DKK 15 billion to be executed during
a 12-month period beginning 1 February 2019.
Under
the programme, initiated 5 November 2019, Novo Nordisk will repurchase B shares for an
amount up to DKK 2.1 billion in the period from 6 November 2019 to 3 February 2020.
Since
the announcement as of 20 December 2019, the following transactions have been made:
|
|
Number of
B shares
|
|
|
Average
purchase price
|
|
|
Transaction
value, DKK
|
|
Accumulated, last announcement
|
|
|
3,205,000
|
|
|
|
|
|
|
|
1,227,729,079
|
|
2 January 2020
|
|
|
100,000
|
|
|
|
389.99
|
|
|
|
38,999,188
|
|
3 January 2020
|
|
|
115,000
|
|
|
|
386.80
|
|
|
|
44,482,127
|
|
6 January 2020
|
|
|
110,000
|
|
|
|
381.71
|
|
|
|
41,987,589
|
|
7 January 2020
|
|
|
100,000
|
|
|
|
383.26
|
|
|
|
38,325,888
|
|
8 January 2020
|
|
|
100,000
|
|
|
|
383.07
|
|
|
|
38,307,451
|
|
9 January 2020
|
|
|
100,000
|
|
|
|
386.72
|
|
|
|
38,671,561
|
|
10 January 2020
|
|
|
77,350
|
|
|
|
391.71
|
|
|
|
30,298,744
|
|
Accumulated under the programme
|
|
|
3,907,350
|
|
|
|
|
|
|
|
1,498,801,627
|
|
The details for each transaction made under the share repurchase programme are published on
novonordisk.com.
Page 2 of 2
With
the transactions stated above, Novo Nordisk owns a total of 48,842,549 B shares of DKK
0.20, corresponding to 2.0% of the share capital, as treasury shares. The total amount
of A and B shares in the company is 2,400,000,000 including treasury shares.
Novo
Nordisk expects to repurchase B shares for an amount up to DKK 15 billion during a 12-month
period beginning 1 February 2019. As of 10 January 2020, Novo Nordisk has since 1 February
2019 repurchased a total of 41,731,273 B shares at an average share price of DKK 344.88
per B share equal to a transaction value of DKK 14,392,474,245.
Novo
Nordisk is a global healthcare company with more than 95 years of innovation and leadership
in diabetes care. This heritage has given us experience and capabilities that also enable
us to help people defeat obesity, haemophilia, growth disorders and other serious chronic
diseases. Headquartered in Denmark, Novo Nordisk employs approximately 42,200 people
in 80 countries and markets its products in more than 170 countries. Novo Nordisk's B
shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York
Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter,
LinkedIn, YouTube.
Further information
Media:
|
|
|
Anne
Margrethe Hauge
|
+45
4442 3450
|
amhg@novonordisk.com
|
Ken
Inchausti (US)
|
+1
609 240 9429
|
kiau@novonordisk.com
|
|
|
|
Investors:
|
|
|
Peter
Hugreffe Ankersen
|
+45
3075 9085
|
phak@novonordisk.com
|
Valdemar
Borum Svarrer
|
+45
3079 0301
|
jvls@novonordisk.com
|
Ann
Søndermølle Rendbæk
|
+45
3075 2253
|
arnd@novonordisk.com
|
Mark
Joseph Root
|
+45
3079 4211
|
mjhr@novonordisk.com
|
Kristoffer
Due Berg (US)
|
+1
609 235 2989
|
krdb@novonordisk.com
|
Novo Nordisk A/S
Investor Relations
|
Novo Allé
2880 Bagsværd
Denmark
|
Telephone:
+45 4444 8888
|
Internet:
www.novonordisk.com
CVR no:
24 25 67 90
|
|
|
Company announcement No 1 / 2020
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf of the undersigned, thereunto duly authorized.
Date: January 13, 2020
|
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer
|
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jun 2024 to Jul 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2023 to Jul 2024